Stereotactic Body Radiotherapy for Spine Oligometastases: A Multicentre Retrospective Study From the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Oligometastases
Spine
Stereotactic body radiotherapy
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
15
04
2023
revised:
26
07
2023
accepted:
04
09
2023
medline:
20
11
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
To evaluate the efficacy of stereotactic body radiotherapy (SBRT) for spine oligometastases. This was a multicentre retrospective study of a series of patients who received SBRT for spine oligometastases. The efficacy of SBRT was evaluated in terms of local control as the primary endpoint. Survival outcomes were also analysed to identify predictive factors for clinical outcomes. Toxicity was assessed according to CTCAE v4.0. Between March 2018 and July 2022, 183 lesions in 177 patients were analysed. In most patients, SBRT was delivered to a single spine metastasis (82%) for a median total dose of 21 Gy (14-35 Gy) in three fractions (one to five fractions) and a median BED In our experience of only oligometastatic patients, spine SBRT gave excellent results in terms of safety and efficacy. Prostate histology and oligorecurrent disease were predictive factors for improved clinical outcomes; also, patients who experienced a further oligoprogression after SBRT maintained a survival advantage compared with polymetastatic progression. No severe adverse events were reported.
Identifiants
pubmed: 37714793
pii: S0936-6555(23)00307-2
doi: 10.1016/j.clon.2023.09.001
pii:
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
794-800Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.